Skip to main content
    C

    Cardiff Oncology Inc (CRDF)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.85
    +0.12 (+16.75%)

    Market Cap: $56.49M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Cardiff Oncology Inc (CRDF) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    Cardiff Oncology reported revenue of $593.00K for the fiscal year ended Dec 31, 2025, down 13.2% from the year before. That year, net income was -$45.85M with a net margin of -7732.0%, operating cash flow was -$37.92M and free cash flow was -$37.97M. The quarter ended Sep 30, 2026 had revenue of $171.00K and net income of -$8.86M.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue grew from $381.07K, a compound annual rate of 5.0%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$593.00K-13.2%100.0%-8256.3%-7732.0%
    Dec 2024$683.00K+40.0%100.0%-7123.1%-6651.7%
    Dec 2023$488.00K+26.4%100.0%-9305.7%-8492.0%
    Dec 2022$386.00K+7.5%100.0%-10337.3%-10026.9%
    Dec 2021$359.00K-1.9%100.0%-8037.6%-7880.5%
    Dec 2020$366.00K+49.6%100.0%-5214.8%-5275.1%
    Dec 2019$244.63K-35.3%100.0%-6817.8%-6709.7%
    Dec 2018$378.32K-25.1%-57.9%-4507.6%-4351.1%
    Dec 2017$505.40K+32.6%-258.4%-5064.4%-4928.1%
    Dec 2016$381.07KN/A-354.1%-10534.9%-10287.7%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$593.00K$683.00K$488.00K$386.00K$359.00K$366.00K$244.63K$378.32K$505.40K$381.07K
    Cost of revenue$0$0$0$0$0$0$0$597.46K$1.81M$1.73M
    Gross profit$593.00K$683.00K$488.00K$386.00K$359.00K$366.00K$244.63K-$219.13K-$1.31M-$1.35M
    Research and development$35.33M$36.85M$32.86M$27.11M$17.38M$11.23M$11.16M$8.16M$7.88M$15.01M
    Operating income-$48.96M-$48.65M-$45.41M-$39.90M-$28.86M-$19.09M-$16.68M-$17.05M-$25.60M-$40.15M
    Net income-$45.85M-$45.43M-$41.44M-$38.70M-$28.29M-$19.31M-$16.41M-$16.46M-$24.91M-$39.20M
    EBITDAN/A-$48.34MN/A-$39.42M-$26.50M-$18.90M-$16.15M-$15.58M-$20.82M-$36.33M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$171.00K$104.00K$41.00K$243.00K$120.00K$121.00K$109.00K$150.00K$165.00K$163.00K$205.00K$156.00K
    Gross profit$171.00K$104.00K$41.00K$243.00K$120.00K$121.00K$109.00K$150.00K$165.00K$163.00K$205.00K$156.00K
    Operating income-$9.22M-$9.62M-$12.85M-$7.83M-$11.97M-$14.78M-$14.38M-$12.57M-$12.60M-$12.54M-$10.93M-$10.33M
    Net income-$8.86M-$9.23M-$12.35M-$7.22M-$11.26M-$13.94M-$13.43M-$11.79M-$11.86M-$11.78M-$10.01M-$9.34M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $730.00K by $16.74M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$61.88M$97.19M$81.64M$116.19M$149.54M$134.73M$13.09M$14.17M$12.28M$43.95M
    Current assets$60.13M$95.05M$77.41M$111.28M$146.13M$133.36M$11.35M$12.77M$9.47M$38.95M
    Cash and equivalents$17.47M$51.47M$21.66M$16.35M$11.94M$130.98M$10.20M$11.45M$8.23M$13.92M
    Total liabilities$16.50M$14.24M$11.90M$9.85M$9.13M$6.57M$5.78M$4.09M$5.78M$24.18M
    Short-term debt$730.00K$710.00K$691.00K$675.00K$551.00K$860.00K$865.38KN/A$1.33M$2.36M
    Long-term debtN/AN/AN/AN/AN/AN/AN/AN/AN/A$14.18M
    Shareholder equity$45.39M$82.95M$69.74M$106.34M$140.42M$128.16M$7.31M$10.08M$6.51M$19.77M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$36.41M$37.33M$49.17M$61.88M$63.78M$75.74M$84.81M$97.19M$62.90M$66.05M$74.04M$81.64M
    Total liabilities$8.32M$10.80M$14.46M$16.50M$14.99M$17.13M$13.93M$14.24M$13.50M$13.66M$13.14M$11.90M
    Cash and equivalents$12.06M$9.20M$8.54M$17.47M$10.13M$10.78M$24.09M$51.47M$13.04M$25.50M$18.66M$21.66M
    Shareholder equity$28.10M$26.53M$34.71M$45.39M$48.79M$58.61M$70.88M$82.95M$49.39M$52.39M$60.89M$69.74M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$37.92M-$37.69M-$30.89M-$33.82M-$23.04M-$16.32M-$13.27M-$13.20M-$23.28M-$31.04M
    Capital expenditures$44.00K$80.00K$582.00K$1.01M$205.00K$211.00K$67.62K$5.10K$101.10K$823.48K
    Free cash flow-$37.97M-$37.77M-$31.47M-$34.83M-$23.25M-$16.53M-$13.34M-$13.20M-$23.38M-$31.86M
    Dividends paidN/AN/AN/A$414.00K$24.00K$24.24M$24.24M$24.24M$24.24M$24.24M
    Share repurchasesN/AN/AN/AN/AN/AN/AN/AN/A$866.04K$79.39K
    Investing cash flow$1.34M$13.73M$36.20M$38.15M-$131.45M-$211.00K-$67.62K$22.84K$23.96M-$24.83M
    Financing cash flow$2.58M$53.78M$0$75.00K$35.45M$137.31M$12.08M$16.40M-$6.38M$2.30M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$9.87M-$11.77M-$12.29M-$5.97M-$10.83M-$8.33M-$12.79M-$10.27M-$10.46M-$9.23M-$7.74M-$7.14M
    Capital expenditures$4.00K$44.00K$0$0$18.00K$26.00K$0$0$0$0$80.00K$8.00K
    Free cash flow-$9.88M-$11.81M-$12.29M-$5.97M-$10.85M-$8.35M-$12.79M-$10.27M-$10.46M-$9.23M-$7.82M-$7.15M
    Last 12 quarters

    Frequently Asked Questions About CRDF

    What is Cardiff Oncology's annual revenue?

    Cardiff Oncology reported revenue of $593.00K for the fiscal year ended Dec 31, 2025.

    How fast is Cardiff Oncology's revenue growing?

    Revenue was down 13.2% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 15.4%.

    Is Cardiff Oncology profitable?

    No. Cardiff Oncology reported net income of -$45.85M for the fiscal year ended Dec 31, 2025, with a net margin of -7732.0%.

    How much free cash flow does CRDF generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$37.92M minus capital expenditures of $44.00K produced free cash flow of -$37.97M.

    How much debt does Cardiff Oncology have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $730.00K and cash and equivalents of $17.47M.